These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20537626)

  • 21. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.
    Rashidi M; Aaleyasin A; Aghahosseini M; Loloi S; Kokab A; Najmi Z
    Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):244-7. PubMed ID: 23541417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of controlled ovarian stimulation for ART in poor responders according to the short protocol using different gonadotrophins combinations.
    Loutradis D; Elsheikh A; Kallianidis K; Drakakis P; Stefanidis K; Milingos S; Michalas S
    Arch Gynecol Obstet; 2004 Dec; 270(4):223-6. PubMed ID: 13680266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.
    Revelli A; Pettinau G; Basso G; Carosso A; Ferrero A; Dallan C; Canosa S; Gennarelli G; Guidetti D; Filippini C; Benedetto C
    Reprod Biol Endocrinol; 2015 Jul; 13():77. PubMed ID: 26209525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled ovarian stimulation with exclusive FSH followed by stimulation with hCG alone, FSH alone or hMG.
    Gomes MK; Vieira CS; Moura MD; Manetta LA; Leite SP; Reis RM; Ferriani RA
    Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):99-106. PubMed ID: 16835006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study.
    Simons AH; Roelofs HJ; Schmoutziguer AP; Roozenburg BJ; van't Hof-van den Brink EP; Schoonderwoerd SA
    Fertil Steril; 2005 Apr; 83(4):889-96. PubMed ID: 15820796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ovarian stimulation with gonadotropins: comparison between recombinant FSH plus menotropins versus recombinant FSH + LH].
    Santibáñez Morales A; Colín Licea EO; Durán Boullosa E; Sánchez Serrano P; Pashkova O
    Ginecol Obstet Mex; 2014 May; 82(5):307-13. PubMed ID: 24937946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The J-Tip Needle-Free Injection System in controlled ovarian hyperstimulation in in vitro fertilization: a pilot study.
    Lavery SA; El-Shawarby SA; Turner C; Trew G
    Fertil Steril; 2008 Nov; 90(5):1969-72. PubMed ID: 18166182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Feb; 107(2):379-386.e4. PubMed ID: 27865446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of neither recombinant nor urinary luteinizing hormone was associated with an improvement in the outcome of autologous in vitro fertilization/intracytoplasmatic sperm injection cycles under regular clinical settings: a multicenter observational analysis.
    Schwarze JE; Crosby JA; Zegers-Hochschild F
    Fertil Steril; 2016 Dec; 106(7):1714-1717.e1. PubMed ID: 27678033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve.
    Musters AM; van Wely M; Mastenbroek S; Kaaijk EM; Repping S; van der Veen F; Mochtar MH
    Hum Reprod; 2012 Jan; 27(1):244-50. PubMed ID: 22095792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures.
    Ruvolo G; Bosco L; Pane A; Morici G; Cittadini E; Roccheri MC
    Fertil Steril; 2007 Mar; 87(3):542-6. PubMed ID: 17126339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial.
    Papanikolaou EG; Fatemi H; Camus M; Kyrou D; Polyzos NP; Humaidan P; Tarlatzis B; Devroey P; Tournaye H
    Fertil Steril; 2010 Dec; 94(7):2902-4. PubMed ID: 20580358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation.
    De Placido G; Alviggi C; Mollo A; Strina I; Ranieri A; Alviggi E; Wilding M; Varricchio MT; Borrelli AL; Conforti S
    Clin Endocrinol (Oxf); 2004 May; 60(5):637-43. PubMed ID: 15104569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after early or midfollicular phase LH supplementation in previous inadequate responders.
    Sönmezer M; Iltemir Duvan C; Ozmen B; Taşçi T; Ozkavukçu S; Atabekoğlu CS
    Reprod Biomed Online; 2010 Mar; 20(3):350-7. PubMed ID: 20093082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A spontaneous luteinizing hormone surge is beneficial in women with unexplained infertility undergoing controlled ovarian hyperstimulation without in vitro fertilization.
    Costello MF; Hughes GJ; Garrett DK; Hanjani A; Steigrad SJ
    Int J Fertil Womens Med; 1998; 43(1):28-33. PubMed ID: 9532467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison between r-LH and urinary supplements containing LH activity in patients undergoing the microdose GnRH agonist flare protocol for in-vitro fertilization: a pilot study.
    Shavit T; Agdi M; Son WY; Hasson J; Dahan MH
    Minerva Ginecol; 2016 Aug; 68(4):393-9. PubMed ID: 26986651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged < 37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study.
    Gholami H; Vicari E; Molis M; La Vignera S; Papaleo E; Cappiello F
    Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):97-102. PubMed ID: 20329567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.